GENE THERAPY INFORMED CONSENT REVISED POINTS-TO-CONSIDER PROPOSAL
Executive Summary
GENE THERAPY INFORMED CONSENT REVISED POINTS-TO-CONSIDER PROPOSAL submitted to members of the Recombinant DNA Advisory Committee April 27 specifies that a separate informed consent document must be submitted for the "gene transfer portion" of a project when gene transfer is used as an adjunct, when the gene is a "marker" or when it is used to "enhance the power of immunotherapy for cancer." The proposal, from Doris Zallen, PhD, Virginia Polytechnic Institute, attempts to answer some of the concerns relating to patients being fully informed of the potential risks and outcomes of human gene therapy that were originally raised by the National Institutes of Health RAC at its Dec. 2-3, 1993 meeting ("The Pink Sheet" Dec. 6, 1993, p. 3).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth